Endocrine therapies, like tamoxifen, aromatase inhibitors, and GnRH agonists, increase diabetes risk potentially by reducing insulin sensitivity and promoting apoptosis in pancreatic β‐cells.31, 56, 57. This evidence concerns the gene CYP19A1 and diabetes mellitus.